Download PDF
Semin Respir Crit Care Med 2002; 23(4): 377-386
DOI: 10.1055/s-2002-34354
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Inhaled Steroids: Are They All Created Equal?

Joseph D. Spahn, Stanley J. Szefler
  • Department of Pediatrics, National Jewish Medical and Research Center, Denver, Colorado; Department of Pediatrics and Pharmacology, University of Colorado Health Sciences Center, Denver, Colorado
Further Information

Publication History

Publication Date:
26 September 2002 (online)

    Permissions and Reprints

ABSTRACT

New inhaled steroids or new formulations of inhaled steroids continue to be introduced on a regular basis in an attempt to replace hydrochlorofluorocarbon propellant-based, pressurized, metered dose delivery systems. New delivery systems are being introduced with either a replacement propellant in a pressurized metered dose inhaler, such as a hydrofluoroalkane, or a dry powder, breath-actuated delivery device. Although there are now many different steroid preparations and delivery devices available, little is known about their relative beneficial and adverse effects. Several recent studies have introduced methods to determine the comparative efficacy of different inhaled steroids as related to a standardized measure of systemic effect. Physicians should be familiar with the differences among the available choices of inhaled steroid-delivery device combinations in order to select therapy that will optimize response and minimize the risk for adverse effects.

KEYWORDS

Inhaled corticosteroids - drug delivery - variability in response

REFERENCES

  • 1 Barnes P J, Pedersen S, Busse W W. Efficacy and safety of inhaled corticosteroids: new developments.  Am J Respir Crit Care Med . 1998;  157 S1-S53
    PubMedGoogle Scholar
  • 2 Busse W W. Inflammation in asthma: the cornerstone of the disease and target of therapy.  J Allergy Clin Immunol . 1999;  102 S17-S22
    PubMedGoogle Scholar
  • 3 Boushey H A. Effect of inhaled corticosteroids on the consequence of asthma.  J Allergy Clin Immunol . 1999;  102 S5-S16
    PubMedGoogle Scholar
  • 4 Global Initiative for Asthma. Global strategy for asthma management and prevention, NHLBI/NIH workshop report. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1995. Publ. No. 95-3659
  • 5 National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1997. Publ. No. 97-4051
    Google Scholar
  • 6 Agertoft L, Pedersen S. Effects of long term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children.  Respir Med . 1994;  88 373-381
    PubMedGoogle Scholar
  • 7 Haahtela T, Jarvinen M, Kava T. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma.  N Engl J Med . 1994;  331 700-705
    CrossrefPubMedGoogle Scholar
  • 8 Selroos O, Pietinalho A, Lofroos A B. Effect of early vs late intervention with inhaled corticosteroids in asthma.  Chest . 1995;  108 1228-1234
    PubMedGoogle Scholar
  • 9 Overbeek S E, Kerstjens H A, Bogaard J M. Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)?.  The Dutch Chronic Nonspecific Lung Disease Study Groups. Chest . 1996;  110 35-41
    PubMedGoogle Scholar
  • 10 Toogood J H, Lefcoe N M, Haines D SM. A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma.  J Allergy Clin Immunol . 1977;  59 298-308
    PubMedGoogle Scholar
  • 11 Toogood J H, Baskerville J, Errington N, Jennings B, Chuang L, Lefcoe N M. Determinants of the response to beclomethasone aerosol at various dosage levels: a multiple regression analysis to identify clinically useful predictors.  J Allergy Clin Immunol . 1977;  60 367-376
    PubMedGoogle Scholar
  • 12 Toogood J H, Baskerville J, Jennings B, Lefcoe N M, Johansson S-A. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma.  J Allergy Clin Immunol . 1989;  84 688-700
    PubMedGoogle Scholar
  • 13 McCubbin M M, Milavetz G, Grandgeorge S. A bioassay for topical and systemic effect of three inhaled corticosteroids.  Clin Pharmacol Ther . 1995;  57 455-460
    CrossrefPubMedGoogle Scholar
  • 14 Seale J P, Harrison L I. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics.  Resp Med . 1998;  9-15 (9-15)
    PubMedGoogle Scholar
  • 15 Vanden Burgt A J, Busse W W, Martin R J, Szefler S J, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma.  J Allergy Clin Immunol . 2000;  106 1209-1226
    CrossrefPubMedGoogle Scholar
  • 16 Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI.  Eur Respir J . 1994;  7 1839-1844
    CrossrefPubMedGoogle Scholar
  • 17 Donnelly R, Williams K M, Baker A B, Badcock C-A, Day R O, Seale J P. Effects of budesonide and fluticasone on 24-hour plasma cortisol: A dose-response study.  Am J Respir Crit Care Med . 1997;  156 1746-1751
    PubMedGoogle Scholar
  • 18 Kelly H W. Establishing a therapeutic index for the inhaled corticosteroids. Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids.  J Allergy Clin Immunol . 1999;  102 S36-S51
    PubMedGoogle Scholar
  • 19 Brus R. Effects of high-dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults.  Arch Intern Med . 1999;  159 1903-1908
    CrossrefPubMedGoogle Scholar
  • 20 Sorkness C A. Establishing a therapeutic index for the inhaled corticosteroids, II: Comparisons of systemic activity and safety among different inhaled corticosteroids.  J Allergy Clin Immunol . 1999;  102 S52-S64
    PubMedGoogle Scholar
  • 21 Clark D J, Grove A, Cargill R I, Lipworth B J. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients.  Thorax . 1996;  51 262-266
    PubMedGoogle Scholar
  • 22 Garbe E, LeLorier J, Boivin J-F, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma.  JAMA . 1997;  277 722-727
    CrossrefPubMedGoogle Scholar
  • 23 Cumming R G, Mitchell P, Leeder S R. Use of inhaled corticosteroids and the risk of cataracts.  N Engl J Med . 1997;  337 8-14
    CrossrefPubMedGoogle Scholar
  • 24 Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients.  JAMA . 1998;  280 539-543
    CrossrefPubMedGoogle Scholar
  • 25 Wong C A, Walsh L J, Smith C JP. Inhaled corticosteroid use and bone-mineral density in patients with asthma.  Lancet . 2000;  355 1399-1403
    CrossrefPubMedGoogle Scholar
  • 26 van der Molen T, de Jong M B, Mulder H H, Postma D S. Starting with a higher dose of inhaled corticosteroids in primary care asthma treatment.  Am J Respir Crit Care Med . 1998;  158 121-125
    PubMedGoogle Scholar
  • 27 Sont J K, Willems L NA, Bel E H, van Krieken J J M H, Vendenbroucke J P, Sterk P J, and the AMPUL Study group. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment.  Am J Respir Crit Care Med . 1999;  159 1043-1051
    CrossrefPubMedGoogle Scholar
  • 28 Peat J K. Asthma: a longitudinal perspective.  J Asthma . 1998;  35 235-241
    PubMedGoogle Scholar
  • 29 Weiss S T. Early life predictors of adult chronic obstructive lung disease.  Eur Respir Rev . 1995;  5 303-309
    PubMedGoogle Scholar
  • 30 Lange P, Parner J, Vestbo J. A 15-year follow-up study of ventilatory function in adults with asthma.  N Engl J Med . 1998;  339 1194-1200
    CrossrefPubMedGoogle Scholar
  • 31 Zeiger R S, Dawson C, Weiss S. Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP).  J Allergy Clin Immunol . 1999;  103 376-387
    PubMedGoogle Scholar
  • 32 Baker J W, Mellon M, Wald J. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants.  Pediatrics . 1999;  103 414-421
    CrossrefPubMedGoogle Scholar
  • 33 Kemp J P, Skoner D P, Szefler S J, Walton-Bowen K, Cruz-Rivera M, Smith J A. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children.  Ann Allergy Asthma Immunol . 1999;  83 231-239
    PubMedGoogle Scholar
  • 34 Shapiro G, Mendelson L, Kraemer M J, Cruz-Rivera M, Walton-Bowen K, Smith J A. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma.  J Allergy Clin Immunol . 1998;  102 789-796
    PubMedGoogle Scholar
  • 35 Kamada A K, Szefler S J, Martin R J. the Asthma Clinical Research Network, et al. Issues in the use of inhaled glucocorticoids.   Am J Respir Crit Care Med . 1996;  153 1739-1748
    PubMedGoogle Scholar
  • 36 Edsbäcker S, Szefler S J. Glucocorticoid pharmacokinetics: principles and clinical applications.  In: Schleimer RP, Busse WW, O'Byrne PM, eds. Topical Glucocorticoids in Asthma: Mechanisms and Clinical Actions. New York: Marcel Dekker; 1996;381-445. Lenfant C, ed. Lung Biology in Health and Diseases Series
    Google Scholar
  • 37 Spahn J D, Szefler S J. Inhaled glucocorticoids, established and new.  In: Yeadon M, Diamant Z, eds. New and Exploratory Therapeutic Agents for Asthma. New York: Marcel Dekker; 2000;307-333. Lenfant C, ed. Lung Biology in Health and Diseases Series, vol 139
    Google Scholar
  • 38 Szefler S J, Boushey H A, Pearlman D S. Time to onset of effect of fluticasone propionate in patients with asthma.   J Allergy Clin Immunol . 1999;  103 780-788
    PubMedGoogle Scholar
  • 39 Noonan M, Chervinsky P, Busse W W. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life.   Am J Respir Crit Care Med . 1995;  152 1467-1473
    PubMedGoogle Scholar
  • 40 Bernstein I L, Fink J. Oral glucocorticosteroid-sparing effect of BUD administered by Turbuhaler: a double blind, placebo-controlled study in adults with moderate to severe chronic asthma.   Chest . 1998;  113 1264-1271
    PubMedGoogle Scholar
  • 41 Karpel J P, Craig T J. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma.  J Allergy Clin Immunol . 2000;  106 852-860
    CrossrefPubMedGoogle Scholar
  • 42 Hummel S, Lehtonen L. Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma.  Lancet . 1992;  340 1483-1487
    CrossrefPubMedGoogle Scholar
  • 43 Lipworth B J. New perspectives on inhaled drug delivery and systemic bioactivity.  Thorax . 1995;  50 105-110
    PubMedGoogle Scholar
  • 44 Storms W W. Risk-benefit assessment of fluticasone propionate in the treatment of asthma and allergic rhinitis.   J Asthma . 1998;  35 313-336
    PubMedGoogle Scholar
  • 45 Pedersen S, Hansen O R. Budesonide treatment of moderate and severe asthma in children: a dose-response study.   J Allergy Clin Immunol . 1995;  95 29-33
    PubMedGoogle Scholar
  • 46 Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis.   BMJ . 2001;  323 1-8
    CrossrefPubMedGoogle Scholar
  • 47 Sher E R, Leung E R, Surs W, Kam J C, Zieg G, Kamada A K, Szefler S J. Steroid-resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy.  J Clin Invest . 1994;  93 33-39
    PubMedGoogle Scholar
  • 48 Martin R J, Szefler S J, Chinchilli V M. for the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network et al. Systemic effect comparisons of six inhaled corticosteroid preparations.  Am J Respir Crit Care Med . 2002;  165 1377-1382
    CrossrefPubMedGoogle Scholar
  • 49 Szefler S J, Martin R J, Sharp King T. for the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network et al. Significant variability in response to inhaled steroids for persistent asthma.  J Allergy Clin Immunol . 2002;  109 410-418
    CrossrefPubMedGoogle Scholar
      >